Retinitis pigmentosa (RP) is the most common hereditary retinal degenerative disorder, leading to vision loss. However, therapeutic delivery to the retina can be challenging: topical applications are limited by rapid drug clearance and bolus intravitreal injections by risk of overdose, inflammation, and cataracts. In light of these poor translational avenues, we are developing a local, sustained release strategy. My project focuses on the application of this drug delivery system in rodent models of RP in order to evaluate its bioavailability and efficacy in vivo – an endeavor that we hope will, one day, overcome vision loss.


University of Toronto
MD/PhD Candidate, 2020-present


MD/PhD Candidate, 2020 - Present